<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112080</article-id><article-id pub-id-type="publisher-id">ACM-40492</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_24946809.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  全髋关节置换术后药物对隐性失血的影响
  Effect of Drugs on Hidden Blood Loss after Total Hip Arthroplasty
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姬</surname><given-names>祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>开斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>建</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>楠楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东第一医科大学(山东省医学科学院)研究生院，山东 泰安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>553</fpage><lpage>558</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    全髋关节置换术(total hip arthroplasty, THA)广泛应用于髋关节退行性变、股骨头坏死、髋关节发育不良等髋关节终末期疾病，取得了很好的疗效。但在围术期失血较多，尤其隐性失血(hidden blood loss, HBL)占比较高，影响了治疗效果。临床上减少围术期隐性失血的方法很多，本文主要从氨甲环酸、抗凝药及中药等方面来阐述药物对隐性失血的影响。
    Total hip arthroplasty (THA) is a widely used method to treat hip degenerative diseases, femoral head necrosis, hip dysplasia and other end-stage hip diseases. However, there is a lot of blood loss during the perioperative period, hidden blood loss (HBL) accounts for a relatively high amount, it affects the therapeutic effect. There are many clinical methods to reduce perioperative recessive blood loss. This article mainly discusses the effect of drugs on hidden blood loss from the aspects of tranexamic acid, anticoagulant and Chinese medicine. 
  
 
</p></abstract><kwd-group><kwd>全髋关节置换术，围手术期，隐性失血，药物, Total Hip Arthroplasty</kwd><kwd> Perioperitive Period</kwd><kwd> Hidden Blood Loss</kwd><kwd> Drugs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>全髋关节置换术(total hip arthroplasty, THA)广泛应用于髋关节退行性变、股骨头坏死、髋关节发育不良等髋关节终末期疾病，取得了很好的疗效。但在围术期失血较多，尤其隐性失血(hidden blood loss, HBL)占比较高，影响了治疗效果。临床上减少围术期隐性失血的方法很多，本文主要从氨甲环酸、抗凝药及中药等方面来阐述药物对隐性失血的影响。</p></sec><sec id="s2"><title>关键词</title><p>全髋关节置换术，围手术期，隐性失血，药物</p></sec><sec id="s3"><title>Effect of Drugs on Hidden Blood Loss after Total Hip Arthroplasty</title><p>Xiang Ji<sup>*</sup>, Kaibin Wei<sup>#</sup>, Jian Zhang, Nannan Yang</p><p>Shandong First Medical University (Shandong Academy of Medical Sciences), Tai’an Shandong</p><p><img src="//html.hanspub.org/file/19-1571907x4_hanspub.png" /></p><p>Received: Jan. 17<sup>th</sup>, 2021; accepted: Feb. 2<sup>nd</sup>, 2021; published: Feb. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/19-1571907x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Total hip arthroplasty (THA) is a widely used method to treat hip degenerative diseases, femoral head necrosis, hip dysplasia and other end-stage hip diseases. However, there is a lot of blood loss during the perioperative period, hidden blood loss (HBL) accounts for a relatively high amount, it affects the therapeutic effect. There are many clinical methods to reduce perioperative recessive blood loss. This article mainly discusses the effect of drugs on hidden blood loss from the aspects of tranexamic acid, anticoagulant and Chinese medicine.</p><p>Keywords:Total Hip Arthroplasty, Perioperitive Period, Hidden Blood Loss, Drugs</p><disp-formula id="hanspub.40492-formula14"><graphic xlink:href="//html.hanspub.org/file/19-1571907x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/19-1571907x8_hanspub.png" /> <img src="//html.hanspub.org/file/19-1571907x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>随着关节外科技术水平的提高，全髋关节置换术(total hip arthroplasty, THA)目前已成为治疗股骨头缺血性坏死、先天性髋关节脱位等关节晚期病变的主要治疗方法。THA能够解除患者关节疼痛及功能障碍，使患者的关节恢复正常功能，从而提高患者的生活质量。研究表明，初次THA的总失血量约在1038 ml至1683 ml之间 [<xref ref-type="bibr" rid="hanspub.40492-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40492-ref2">2</xref>]，失血量大，从而降低机体抵抗力，会导致术后贫血，增加发生刀口感染，刀口愈合不良，关节功能恢复速度减慢，患者下地时间延迟等并发症。Liu等人研究表明，隐性失血占总失血量约60% [<xref ref-type="bibr" rid="hanspub.40492-ref3">3</xref>]，明确隐性失血(hidden blood loss, HBL)这一概念可以帮助临床医生更准确的评估患者围术期的失血量，进一步确保患者围术期的安全 [<xref ref-type="bibr" rid="hanspub.40492-ref4">4</xref>]。目前已有多种方法来减少隐性失血，本文主要从药物对隐性失血的影响方面进行综述。</p></sec><sec id="s6"><title>2. 隐性失血</title><sec id="s6_1"><title>2.1. 隐性失血的机制</title><p>1) 血液进入组织间隙，积存在关节腔中。Sehat [<xref ref-type="bibr" rid="hanspub.40492-ref5">5</xref>] 等人的研究表明，隐性失血主要是血液渗透入组织间隙，关节腔内残余及溶血导致的，约占总失血量的一半，在无输血的情况下，隐性失血主要由渗透入组织间隙的血液组成，在输血的情况下，隐性失血主要是由渗透入组织间隙的血液(约占60%)和溶血(约占35%)两部分组成。Erskine [<xref ref-type="bibr" rid="hanspub.40492-ref6">6</xref>] 认为关节置换术后部分血液进入组织间隙，积存在关节腔中导致隐性失血，该部分约占总出血量的1/2。</p><p>2) 溶血。Pattison [<xref ref-type="bibr" rid="hanspub.40492-ref7">7</xref>] 研究THA和全膝关节置换术(total knee arthroplasty, TKA)术后血红蛋白(Hemoglobin, Hb)下降幅度时发现术后记录出血量与Hb下降幅度不相符，认为溶血可能导致隐性失血。Faris [<xref ref-type="bibr" rid="hanspub.40492-ref8">8</xref>] 等人研究发现，自体血回输会发生溶血，但溶血程度不足以产生血红蛋白尿，也使得隐性失血量增加。</p><p>3) 其他因素。凝血因子活性及凝血物质改变、红细胞损伤、毛细血管通透性等因素也可能导致隐性失血。当前对于隐性失血的发生机制还尚未完全明确，有待于进一步研究。</p></sec><sec id="s6_2"><title>2.2. 隐性失血的计算方式</title><p>按照Gross [<xref ref-type="bibr" rid="hanspub.40492-ref9">9</xref>] 方程式：1) 失血总量 = 显性失血量 + 隐性失血量 − 异体输血量。2) 显性失血量 = 术中失血量(术中纱布渗血量 + 术中出血量) + 术后失血量(术后引流量 + 术后换药纱布渗血量)。3) 总失血量理论值 = 术前血容量(patient blood volume PBV) &#215; (术前红细胞比容 − 术后红细胞比容)；术前血容量 = K1 &#215; 身高<sup>3</sup> + K2 &#215; 体重 + K3 (男性：K1 = 0.3369, K2 = 0.3219, K3 = 0.6041；女性：K1 = 0.3561, K2 = 0.3308, K3 = 0.1833)。4) 失血总量 = 总失血量理论值/HCT均值。</p></sec></sec><sec id="s7"><title>3. 影响围术期隐性失血的药物因素</title><sec id="s7_1"><title>3.1. 氨甲环酸</title><p>氨甲环酸(Tranexamic acid, TXA)是一种赖氨酸衍生物，能够强烈吸附纤溶酶和纤溶酶原上的纤维蛋白结合部位的赖氨酸结合位点，阻抑了纤溶酶、纤溶酶原与纤维蛋白的结合，从而抑制纤维蛋白的分解，减少进一步的失血。目前，TXA已经广泛应用于THA中，许多文献也证实了TXA能够减少THA术后的出血量，并且不增加深静脉血栓(Deep vein thrombosis, DVT)等并发症的风险 [<xref ref-type="bibr" rid="hanspub.40492-ref10">10</xref>]。</p><sec id="s7_1_1"><title>3.1.1. 氨甲环酸使用剂量及用药时间</title><p>目前TXA的最佳剂量、使用时间、给药次数等问题，还没有得到大家的共识。Ker等人的研究表明，术前10~20 mg/kg是TXA的安全有效使用剂量 [<xref ref-type="bibr" rid="hanspub.40492-ref11">11</xref>]。Xie [<xref ref-type="bibr" rid="hanspub.40492-ref12">12</xref>] 等通过对照研究发现，与切口前单次静脉注射TXA方案(切口前TXA 20 mg/kg)相比，三次静脉注射TXA方案(切口前TXA 20 mg/kg，术后3小时，6小时1 g/100ml TXA)可使术后第三天平均HBL降低40.8%且使Hb下降幅度减小；与两次TXA剂量方案(切口前TXA 20 mg/kg，术后3小时1 g/100ml TXA)相比，三次TXA方案可使术后平均HBL降低28.3%且使Hb水平较两次方案下降减小，由此可以得到多次静脉应用TXA可有效降低初次THA术后的HBL，降低血红蛋白下降幅度，减少术后并发症。Lei的一项随机对照试验也证明，多次静脉给与TXA可降低患者全髋关节置换术后的平均HBL，总失血量(total blood loss, TBL)以及最大血红蛋白下降值 [<xref ref-type="bibr" rid="hanspub.40492-ref13">13</xref>]。</p></sec><sec id="s7_1_2"><title>3.1.2. 氨甲环酸用药途径</title><p>当前在THA中，TXA有多种使用方法，可以静脉、局部、口服或多途径给药，目前尚未研究出TXA的最佳使用方法。临床中TXA的使用方式与临床医生习惯有关。</p><p>Liu [<xref ref-type="bibr" rid="hanspub.40492-ref14">14</xref>] 的荟萃分析中表明，与单独使用静脉应用TXA相比，将静脉和局部TXA联合用于THA的患者可以减少总失血量，而不会增加术后并发症的风险。Vles [<xref ref-type="bibr" rid="hanspub.40492-ref15">15</xref>] 等人通过对比THA手术结束前筋膜下引流管局部应用TXA和闭合伤口前静脉应用TXA两种方案，认为局部应用和静脉应用TXA对隐性失血有相似的作用效果。而Ni [<xref ref-type="bibr" rid="hanspub.40492-ref16">16</xref>] 等人的研究则认为与静脉给药组(麻醉10 min前以10 mg/kg的剂量向患者静脉内给予TXA)相比，局部用药组(将3 g TXA溶于120 ml盐水的溶液分成三等份，在髋臼制备后用一块纱布和40 ml氨甲环酸浸泡髋臼5分钟；在制备股管开口后，将另一根浸泡40 ml TXA盐水溶液的纱布条插入股管中5分钟；筋膜闭合后，将剩余的40 ml TXA溶液注入髋关节)可以有效减少THA中的TBL、HBL、术后输血率而不会增加静脉血栓的风险。</p><p>Zhang [<xref ref-type="bibr" rid="hanspub.40492-ref17">17</xref>] 的一项meta分析指出，相比于静脉或局部单独应用TXA，静脉+局部联合应用TXA的患者术后总出血量、术后血红蛋白的下降和输血率均较低，且血栓事件发生率无明显增加。Wang [<xref ref-type="bibr" rid="hanspub.40492-ref18">18</xref>] 等人的Meta分析中，比较TXA + 稀释肾上腺素(Dilute adrenaline DEP)与单纯TXA降低失血的疗效，发现静脉应用TXA + DEP显著降低了THA患者的输血需求、总失血量和隐性失血量，且不增加DVT的发生，但是需要额外的长期追踪来确定TXA和DEP的最佳剂量。Teng [<xref ref-type="bibr" rid="hanspub.40492-ref19">19</xref>] 等人的一项荟萃分析中表明，DEP能显著减少全关节置换(TJA)的术后出血量，而不增加DVT的发生率，但是静脉注射DEP后，术中出血量，术后血红蛋白丢失和输血率均无明显下降。Cao等人 [<xref ref-type="bibr" rid="hanspub.40492-ref20">20</xref>] 的研究认为多次口服TXA可以进一步减少THA术后失血，Hb和Hct下降，并抑制初次THA术后纤溶，而不会增加发生并发症的风险。Kayupov [<xref ref-type="bibr" rid="hanspub.40492-ref21">21</xref>] 等人认为与静脉应用TXA相比，口服TXA在减少术中失血方面有相同的作用效果，且成本大大降低。Cao等人 [<xref ref-type="bibr" rid="hanspub.40492-ref22">22</xref>] 研究得出术后多次口服TXA (术后4 h、10 h、16 h口服TXA 3 g)和静脉应用TXA (切口前静脉注射TXA 20 mg/kg，术后6 h、12 h、18 h静脉注射TXA 1 g)在减少初次THA的失血，Hb和Hct的下降方面具有相同的效果，而不会增加血栓栓塞性疾病和伤口并发症的风险的结论。</p></sec></sec><sec id="s7_2"><title>3.2. 抗凝药</title><p>THA术后患者失血量较大，机体处于高凝状态，使得患者术后DVT和肺栓塞的发生风险增加。研究表明，若THA术后不采取预防措施，深静脉血栓形成的发生率约为51% [<xref ref-type="bibr" rid="hanspub.40492-ref23">23</xref>]，致死性肺栓塞的发生率约为2% [<xref ref-type="bibr" rid="hanspub.40492-ref24">24</xref>]。术后4、5、6天发生深静脉血栓的风险最高，术后2周以后风险逐步降低 [<xref ref-type="bibr" rid="hanspub.40492-ref25">25</xref>]。为降低该并发症的发生，术后常用抗凝药物进行治疗。</p><p>李军 [<xref ref-type="bibr" rid="hanspub.40492-ref26">26</xref>] 等通过随机对照试验发现利伐沙班在对TKA术后隐性失血的影响等同于依诺肝素钠，但依诺肝素钠相比利伐沙班会增加TKA术后显性失血。高乐才 [<xref ref-type="bibr" rid="hanspub.40492-ref27">27</xref>] 等人发现利伐沙班在预防TKA术后静脉血栓形成方面等效于低分子肝素，但两者均可使隐性失血量增加，且利伐沙班的隐性失血量增加显著低于低分子肝素，并且利伐沙班是口服给药，患者依从性较高。</p></sec><sec id="s7_3"><title>3.3. 中药</title><p>近些年来，中药减少THA围术期隐性失血引起了国内学者的广泛关注。肖学锋 [<xref ref-type="bibr" rid="hanspub.40492-ref28">28</xref>] 认为复元活血汤能减少全髋关节置换术后的隐性失血量，但对显性失血无疗效。邱庆虎 [<xref ref-type="bibr" rid="hanspub.40492-ref29">29</xref>] 等人研究认为全髋关节置换术后口服八珍汤可以减少围手术期隐性失血，提高骨髓造血能力。肖署阳 [<xref ref-type="bibr" rid="hanspub.40492-ref30">30</xref>] 认为三七止血汤能在人工全髋关节置换术中显著减少总失血量、显性失血量及隐性失血量，并降低患者输血量及输血患者数量。吴泽庭 [<xref ref-type="bibr" rid="hanspub.40492-ref31">31</xref>] 发现了归脾汤能减少THA术后隐性失血量，并降低术后血红蛋白(Heamoglobin, Hb)的丢失速度及血细胞比容(Hematocrit, Hct)的下降幅度。但是，中药对于THA术后隐性失血的研究存在不足之处，比如无法完全排除相关影响因素，样本量较小等。</p></sec></sec><sec id="s8"><title>4. 讨论与小结</title><p>综上所述，全髋关节置换术后的药物使用对于围术期的隐性失血作用较大。TXA能显著减少THA围术期出血，并不增加VTE的风险。多次静脉应用TXA在减少THA围术期隐性失血方面效果优于单次静脉注射。静脉应用TXA与局部应用在减少THA围术期失血方面有相似的作用。口服TXA也被证实能够减少THA术后失血，且效果与静脉应用TXA相似。静脉+局部联合应用TXA相比于单一用药方式更有效，且不增加VTE风险。早些年THA术后应用低分子肝素出血风险高于华法林，但血栓发生率低于华法林组。近年来，利伐沙班预防静脉血栓方面的等效于低分子肝素，但增加隐性失血方面少于低分子肝素，且依从性较好，临床应用较为广泛。八珍汤、复原活血汤、三七止血汤及归脾汤均可减少THA术后隐性失血，但由于样本量较小，无法排除相关因素影响，需要大样本进行对照研究。</p></sec><sec id="s9"><title>文章引用</title><p>姬 祥,魏开斌,张 建,杨楠楠. 全髋关节置换术后药物对隐性失血的影响Effect of Drugs on Hidden Blood Loss after Total Hip Arthroplasty[J]. 临床医学进展, 2021, 11(02): 553-558. https://doi.org/10.12677/ACM.2021.112080</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40492-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Claeys, M.A., Vermeersch, N. and Haentjens, P. (2007) Reduction of Blood Loss with Tranexamic Acid in Primary Total Hip Replacement Surgery. Acta Chirurgica Belgica, 107, 397-401.  
&lt;br&gt;https://doi.org/10.1080/00015458.2007.11680081</mixed-citation></ref><ref id="hanspub.40492-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rajesparan, K., Biant, L.C., Ahmad, M., et al. (2009) The Effect of an Intravenous Bolus of Tranexamic Acid on Blood Loss in Total Hip Replacement. Journal of Bone and Joint Surgery, 91, 776-783.  
&lt;br&gt;https://doi.org/10.1302/0301-620X.91B6.22393</mixed-citation></ref><ref id="hanspub.40492-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Zhang, X., Chen, Y., et al. (2011) Hidden Blood Loss after Total Hip Arthroplasty. The Journal of Arthroplasty, 26, 1100-1105. &lt;br&gt;https://doi.org/10.1016/j.arth.2010.11.013</mixed-citation></ref><ref id="hanspub.40492-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Y.S., Zhang, H., Zheng, W.H., et al. (2017) Hidden Blood Loss and the Influential Factors after Percutaneous Kyphoplasty Surgery. European Spine Journal, 26, 1878-1883. &lt;br&gt;https://doi.org/10.1007/s00586-017-4950-9</mixed-citation></ref><ref id="hanspub.40492-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sehat, K.R., Evans, R. and Newman, J.H. (2000) How Much Blood Is Really Lost in Total Knee Arthroplasty? Correct Blood Loss Management Should Take Hidden Loss into Account. Knee, 7, 151-155.  
&lt;br&gt;https://doi.org/10.1016/S0968-0160(00)00047-8</mixed-citation></ref><ref id="hanspub.40492-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Erskine, J.G., Fraser, C., Simpson, R., et al. (1981) Blood Loss with Knee Joint Replacement. Journal of the Royal College of Surgeons of Edinburgh, 26, 295-297.</mixed-citation></ref><ref id="hanspub.40492-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Pattison, E., Protheroe, K., Pringle, R.M., et al. (1973) Reduction in Haemoglobin after Knee Joint Surgery. Annals of the Rheumatic Diseases, 32, 582-584. &lt;br&gt;https://doi.org/10.1136/ard.32.6.582</mixed-citation></ref><ref id="hanspub.40492-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Faris, P.M., Ritter, M.A., Keating, E.M., et al. (1991) Unwashed Filtered Shed Blood Collected after Knee and Hip Arthroplasties. The Journal of Bone and Joint Surgery, 73A, 1169-1178.  
&lt;br&gt;https://doi.org/10.2106/00004623-199173080-00005</mixed-citation></ref><ref id="hanspub.40492-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gross, J.B. (1983) Estimating Allowable Blood Loss: Corrected for Dilution. Anesthesiology, 58, 277-280.  
&lt;br&gt;https://doi.org/10.1097/00000542-198303000-00016</mixed-citation></ref><ref id="hanspub.40492-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Williams-Johnson, J.A., McDonald, A.H., Strachan, G.G., et al. (2010) Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-Controlled Trial. West Indian Medical Journal, 59, 612-624.</mixed-citation></ref><ref id="hanspub.40492-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ker, K., Edwards, P., Perel, P., et al. (2012) Effect of Tranexamic Acid on Surgical Bleeding: Systematic Review and Cumulative Meta-Analysis. BMJ, 344, 3054. &lt;br&gt;https://doi.org/10.1136/bmj.e3054</mixed-citation></ref><ref id="hanspub.40492-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Xie, J., Hu, Q., Ma, J., et al. (2017) Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss and the Inflammatory Response Following Enhanced-Recovery Primary Total Hip Arthroplasty: A Randomised Clinical Trial. The Bone &amp; Joint Journal, 99, 1442-1449. &lt;br&gt;https://doi.org/10.1302/0301-620X.99B11.BJJ-2017-0488.R1</mixed-citation></ref><ref id="hanspub.40492-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lei, Y., Huang, Q., Huang, Z., et al. (2018) Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss after Total Hip Arthroplasty: A Randomized Controlled Trial. The Journal of Arthroplasty, 33, 2940-2945.  
&lt;br&gt;https://doi.org/10.1016/j.arth.2018.04.024</mixed-citation></ref><ref id="hanspub.40492-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Liu, J. and Sun, G. (2017) A Comparison of Combined Intravenous and Topical Administration of Tranexamic Acid with Intravenous Tranexamic Acid Alone for Blood Loss Reduction after Total Hip Arthroplasty: A Meta-Analysis. International Journal of Surgery, 41, 34-43. &lt;br&gt;https://doi.org/10.1016/j.ijsu.2017.03.031</mixed-citation></ref><ref id="hanspub.40492-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Vles, G.F., Corten, K., Driesen, R., et al. (2020) Hidden Blood Loss in Direct Anterior Total Hip Arthroplasty: A Prospective, Double Blind, Randomized Controlled Trial on Topical versus Intravenous Tranexamic Acid. Musculoskeletal Surgery. &lt;br&gt;https://doi.org/10.1007/s12306-020-00652-0</mixed-citation></ref><ref id="hanspub.40492-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ni, J.R., Wang, L.X. and Chen, X.J. (2016) Comparison of Different Modes of Using Tranexamic Acid Administration on Reducing Hidden Blood Loss in Total Hip Arthroplasty. China Journal of Orthopaedics and Traumatology, 29, 713-717.</mixed-citation></ref><ref id="hanspub.40492-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, P., Liang, Y., Chen, P., et al. (2017) Combined Application versus Topical and Intravenous Application of Tranexamic Acid Following Primary Total Hip Arthroplasty: A Meta-Analysis. BMC Musculoskeletal Disorder, 18, 90.  
&lt;br&gt;https://doi.org/10.1186/s12891-017-1429-0</mixed-citation></ref><ref id="hanspub.40492-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z. and Zhang, H.J. (2018) Comparative Effectiveness and Safety of Tranexamic Acid plus Diluted Epinephrine to Control Blood Loss during Total Hip Arthroplasty: A Meta-Analysis. Journal of Orthopaedic Surgery and Research, 13, 242. &lt;br&gt;https://doi.org/10.1186/s13018-018-0948-1</mixed-citation></ref><ref id="hanspub.40492-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Teng, Y., Ma, J., Ma, X., et al. (2017) The Efficacy and Safety of Epinephrine for Postoperative Bleeding in Total Joint Arthroplasty: A PRISMA-Compliant Meta-Analysis. Medicine (Baltimore), 96, e6763.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000006763</mixed-citation></ref><ref id="hanspub.40492-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cao, G., Huang, Q., Huang, Z., et al. (2019) The Efficacy and Safety of Multiple-Dose Oral Tranexamic Acid on Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. International Orthopaedics, 43, 299-305. &lt;br&gt;https://doi.org/10.1007/s00264-018-3925-8</mixed-citation></ref><ref id="hanspub.40492-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kayupov, E., Fillingham, Y.A., Okroj, K., et al. (2017) Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. Journal of Bone and Joint Surgery, 99, 373-378. &lt;br&gt;https://doi.org/10.2106/JBJS.16.00188</mixed-citation></ref><ref id="hanspub.40492-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Cao, G., Huang, Z., Xie, J., et al. (2018) The Effect of Oral versus Intravenous Tranexamic Acid in Reducing Blood Loss after Primary Total Hip Arthroplasty: A Randomized Clinical Trial. Thrombosis Research, 164, 48-53.  
&lt;br&gt;https://doi.org/10.1016/j.thromres.2018.02.007</mixed-citation></ref><ref id="hanspub.40492-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Clagett, G.P., Anderson, F.A., Heit, J., et al. (1995) Prevention of Venous Thromboembolism. Chest, 108, 312S-334S.  
&lt;br&gt;https://doi.org/10.1378/chest.108.4_Supplement.312S</mixed-citation></ref><ref id="hanspub.40492-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Haake, D.A. and Berkman, S.A. (1989) Venous Thromboembolic Disease after Hip Surgery. Risk Factors, Prophylaxis and Diagnosis. Clinical Orthopaedics and Related Research, 242, 212-231.  
&lt;br&gt;https://doi.org/10.1097/00003086-198905000-00022</mixed-citation></ref><ref id="hanspub.40492-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">(1986) Prevention of Venous Thrombosis and Pulmonary Embolism. National Institutes of Health Consensus Development Conference Statement, 6, 1-8.</mixed-citation></ref><ref id="hanspub.40492-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">李军, 荆珏华, 周云, 等. 利伐沙班和依诺肝素钠对人工全膝关节置换术后失血风险的影响比较[J]. 中国修复重建外科杂志, 2014, 28(1): 26-29.</mixed-citation></ref><ref id="hanspub.40492-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">高乐才, 武永东, 邵明星, 等. 低分子肝素及利伐沙班对全髋关节置换术后隐性失血的影响[J]. 现代中西医结合杂志, 2014, 23(22): 2453-2455.</mixed-citation></ref><ref id="hanspub.40492-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">肖学峰. 复元活血汤治疗生物型全髋关节置术后隐性失血气滞血瘀证的临床疗效观察[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2019.</mixed-citation></ref><ref id="hanspub.40492-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">邱庆虎, 马松涛, 李印鹏, 等. 八珍汤对老年全髋关节置换术后隐性失血的影响[J]. 中国中医骨伤科杂志, 2019, 27(1): 27-30.</mixed-citation></ref><ref id="hanspub.40492-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">肖署阳, 蔡立民, 谭志超, 等. 三七止血汤治疗人工全髋关节置换术围手术期失血临床研究[J]. 新中医, 2020, 52(2): 89-92.</mixed-citation></ref><ref id="hanspub.40492-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">吴泽庭. 归脾汤对单侧全髋关节置换术围手术期隐性失血的影响研究[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2019.</mixed-citation></ref></ref-list></back></article>